Development and validation of a predictive model for new-onset atrial fibrillation in sepsis based on clinical risk factors.

OBJECTIVE

New-onset atrial fibrillation (NOAF) is a common complication and one of the primary causes of increased mortality in critically ill adults. Since early assessment of the risk of developing NOAF is difficult, it is critical to establish predictive tools to identify the risk of NOAF.

METHODS

We retrospectively enrolled 1,568 septic patients treated at Wuhan Union Hospital (Wuhan, China) as a training cohort. For external validation of the model, 924 patients with sepsis were recruited as a validation cohort at the First Affiliated Hospital of Xinjiang Medical University (Urumqi, China). Least absolute shrinkage and selection operator (LASSO) regression and multivariate logistic regression analyses were used to screen predictors. The area under the ROC curve (AUC), calibration curve, and decision curve were used to assess the value of the predictive model in NOAF.

RESULTS

A total of 2,492 patients with sepsis (1,592 (63.88%) male; mean [SD] age, 59.47 [16.42] years) were enrolled in this study. Age (OR: 1.022, 1.009-1.035), international normalized ratio (OR: 1.837, 1.270-2.656), fibrinogen (OR: 1.535, 1.232-1.914), C-reaction protein (OR: 1.011, 1.008-1.014), sequential organ failure assessment score (OR: 1.306, 1.247-1.368), congestive heart failure (OR: 1.714, 1.126-2.608), and dopamine use (OR: 1.876, 1.227-2.874) were used as risk variables to develop the nomogram model. The AUCs of the nomogram model were 0.861 (95% CI, 0.830-0.892) and 0.845 (95% CI, 0.804-0.886) in the internal and external validation, respectively. The clinical prediction model showed excellent calibration and higher net clinical benefit. Moreover, the predictive performance of the model correlated with the severity of sepsis, with higher predictive performance for patients in septic shock than for other patients.

CONCLUSION

The nomogram model can be used as a reliable and simple predictive tool for the early identification of NOAF in patients with sepsis, which will provide practical information for individualized treatment decisions.